Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer

Kimberly Johung, Amar Rewari, Hao Wu, Benjamin Judson, Joseph N. Contessa, Bruce Haffty, Roy H. Decker

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. Methods ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. Results ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% (p =.78) and overall survival was 68% versus 54% (p =.65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.

Original languageEnglish (US)
Pages (from-to)852-857
Number of pages6
JournalHead and Neck
Volume35
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Laryngeal Neoplasms
DNA Repair
Radiotherapy
Survival
Tissue Array Analysis
Chemoradiotherapy
Platinum
Squamous Cell Carcinoma
Multivariate Analysis
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Keywords

  • excision repair cross-complementation 1
  • head and neck cancer
  • laryngeal cancer
  • radiation therapy
  • tissue microarray

Cite this

Johung, Kimberly ; Rewari, Amar ; Wu, Hao ; Judson, Benjamin ; Contessa, Joseph N. ; Haffty, Bruce ; Decker, Roy H. / Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer. In: Head and Neck. 2013 ; Vol. 35, No. 6. pp. 852-857.
@article{242d415a00cc4f94ad961fb475b330f3,
title = "Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer",
abstract = "Background High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. Methods ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. Results ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75{\%} versus 71{\%} (p =.78) and overall survival was 68{\%} versus 54{\%} (p =.65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.",
keywords = "excision repair cross-complementation 1, head and neck cancer, laryngeal cancer, radiation therapy, tissue microarray",
author = "Kimberly Johung and Amar Rewari and Hao Wu and Benjamin Judson and Contessa, {Joseph N.} and Bruce Haffty and Decker, {Roy H.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1002/hed.23041",
language = "English (US)",
volume = "35",
pages = "852--857",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer. / Johung, Kimberly; Rewari, Amar; Wu, Hao; Judson, Benjamin; Contessa, Joseph N.; Haffty, Bruce; Decker, Roy H.

In: Head and Neck, Vol. 35, No. 6, 01.06.2013, p. 852-857.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer

AU - Johung, Kimberly

AU - Rewari, Amar

AU - Wu, Hao

AU - Judson, Benjamin

AU - Contessa, Joseph N.

AU - Haffty, Bruce

AU - Decker, Roy H.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Background High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. Methods ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. Results ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% (p =.78) and overall survival was 68% versus 54% (p =.65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.

AB - Background High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. Methods ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. Results ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% (p =.78) and overall survival was 68% versus 54% (p =.65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.

KW - excision repair cross-complementation 1

KW - head and neck cancer

KW - laryngeal cancer

KW - radiation therapy

KW - tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=84878018835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878018835&partnerID=8YFLogxK

U2 - 10.1002/hed.23041

DO - 10.1002/hed.23041

M3 - Article

C2 - 22740347

AN - SCOPUS:84878018835

VL - 35

SP - 852

EP - 857

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 6

ER -